IMVT - NASDAQ
Immunovant, Inc.
$31.15
+1.2%Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
At a Glance
Live SnapshotImmunovant, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immunovant, Inc. Balance Sheet
IMVT • NASDAQ
| Immunovant, Inc. Balance Sheet | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
902.1M | 714M | 635.4M | 376.5M | 493.8M | 400.1M | 100.6M | 325K | 0.0 | |
902.1M | 714M | 635.4M | 376.5M | 493.8M | 400.1M | 100.6M | 325K | 0.0 | |
1.1M | 2.5M | 5.5M | 885K | 12.9M | 1.1M | 3M | 0.0 | 0.0 | |
0.0 | 2.1M | 5.3M | 700K | 12.2M | 596K | 0.0 | 0.0 | 0.0 | |
0.0 | 427K | 166K | 185K | 632K | 548K | 3M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 26.9M | 6.3M | 7.7M | 5.5M | 0.0 | 113.2K | |
45.6M | 51.2M | 24.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
948.8M | 767.7M | 665.8M | 404.3M | 512.9M | 409M | 109.1M | 325K | 113.2K | |
NON-CURRENT ASSETS | |||||||||
515K | 942K | 595K | 1.5M | 2.6M | 3.5M | 65K | 0.0 | 0.0 | |
0.0 | 0.0 | 347K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
7.7M | 7.6M | 0.0 | 0.0 | 0.0 | 0.0 | 246K | 79.9K | 0.0 | |
8.2M | 8.6M | 942K | 1.5M | 2.6M | 3.5M | 311K | 80K | 0.0 | |
957M | 776.2M | 666.7M | 405.8M | 515.6M | 412.5M | 109.4M | 405K | 113.2K | |
LIABILITIES | |||||||||
CURRENT LIABILITIES | |||||||||
0.0 | 17.9M | 7.2M | 1.4M | 18.6M | 2.4M | 1.2M | 0.0 | 1.1M | |
7.5M | 17.7M | 7.2M | 1.4M | 18.6M | 2.4M | 1.2M | 0.0 | 1.1M | |
0.0 | 273K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 35.1M | 14.7M | 40.4M | 24.6M | 12M | 0.0 | 80.4K | 474K | |
72K | 0.0 | 138K | 0.0 | 0.0 | 0.0 | 3.2M | 300K | 0.0 | |
0.0 | 98K | 0.0 | 1.2M | 1.1M | 1.2M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -206.0 | 0.0 | |
104.4M | 15.6M | 26.6M | 350K | 171K | 3.1M | 10.9M | -206.0 | 0.0 | |
104.4M | 68.8M | 48.6M | 43.3M | 44.5M | 18.8M | 15.3M | 380.4K | 1.6M | |
NON-CURRENT LIABILITIES | |||||||||
0.0 | 0.0 | 347K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 347K | 47K | 1.2M | 2.2M | 0.0 | 300K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -300K | 0.0 | |
0.0 | 98K | 0.0 | 1.2M | 2.4M | 3.4M | 0.0 | 0.0 | 0.0 | |
104.4M | 68.8M | 49M | 43.3M | 45.7M | 21M | 15.3M | 380.4K | 1.6M | |
SHAREHOLDERS' EQUITY | |||||||||
20K | 16K | 14K | 13K | 12K | 10K | 5K | 288.0 | 0.0 | |
0.0 | 1.9B | 1.4B | 928M | 824.8M | 590.4M | 185.3M | 24.7K | 0.0 | |
-1.7B | -1.2B | -825.7M | -566.3M | -355.4M | -198.7M | -91.2M | -448.0 | 0.0 | |
730K | 1.5M | 1.9M | 852K | 404K | -298K | -16K | 343K | -1.5M | |
2.6B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
852.6M | 707.4M | 617.8M | 362.5M | 469.8M | 391.5M | 94.1M | 24.6K | -1.5M | |
852.6M | 707.4M | 617.8M | 362.5M | 469.8M | 391.5M | 94.1M | 24.6K | -1.5M | |
SUMMARY | |||||||||
957M | 776.2M | 666.7M | 405.8M | 515.6M | 412.5M | 109.4M | 405K | 113.2K | |
72K | 98K | 138K | 1.2M | 2.4M | 3.4M | 3.2M | 300K | 0.0 | |
-902M | -713.9M | -635.2M | -375.3M | -491.5M | -396.7M | -97.4M | -25K | 0.0 | |
175,276,526 | 175,276,526 | 175,276,526 | 175,276,526 | 175,276,526 | 175,276,526 | 175,276,526 | 175,276,526 | 175,276,526 |
SEC Filings
IMVT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2026 FY FY | May 20, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 20, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 06, 2026 | February 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 21, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 03, 2025 | September 03, 2025 | 2025 |
Related Guides
Continue your IMVT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.